425 related articles for article (PubMed ID: 16597723)
1. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.
Lee JT; Wheeler TC; Li L; Chin LS
Hum Mol Genet; 2008 Mar; 17(6):906-17. PubMed ID: 18065497
[TBL] [Abstract][Full Text] [Related]
5. Parkin and defective ubiquitination in Parkinson's disease.
Dawson TM
J Neural Transm Suppl; 2006; (70):209-13. PubMed ID: 17017531
[TBL] [Abstract][Full Text] [Related]
6. Co-association of parkin and alpha-synuclein.
Choi P; Golts N; Snyder H; Chong M; Petrucelli L; Hardy J; Sparkman D; Cochran E; Lee JM; Wolozin B
Neuroreport; 2001 Sep; 12(13):2839-43. PubMed ID: 11588587
[TBL] [Abstract][Full Text] [Related]
7. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
8. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Schlossmacher MG; Frosch MP; Gai WP; Medina M; Sharma N; Forno L; Ochiishi T; Shimura H; Sharon R; Hattori N; Langston JW; Mizuno Y; Hyman BT; Selkoe DJ; Kosik KS
Am J Pathol; 2002 May; 160(5):1655-67. PubMed ID: 12000718
[TBL] [Abstract][Full Text] [Related]
9. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
Chung KK; Zhang Y; Lim KL; Tanaka Y; Huang H; Gao J; Ross CA; Dawson VL; Dawson TM
Nat Med; 2001 Oct; 7(10):1144-50. PubMed ID: 11590439
[TBL] [Abstract][Full Text] [Related]
10. Pathological proteins in Parkinson's disease: focus on the proteasome.
Snyder H; Wolozin B
J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264
[TBL] [Abstract][Full Text] [Related]
11. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
12. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.
Liani E; Eyal A; Avraham E; Shemer R; Szargel R; Berg D; Bornemann A; Riess O; Ross CA; Rott R; Engelender S
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5500-5. PubMed ID: 15064394
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Parkin and
Madsen DA; Schmidt SI; Blaabjerg M; Meyer M
Cells; 2021 Jan; 10(2):. PubMed ID: 33572534
[TBL] [Abstract][Full Text] [Related]
16. Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.
Brahmachari S; Lee S; Kim S; Yuan C; Karuppagounder SS; Ge P; Shi R; Kim EJ; Liu A; Kim D; Quintin S; Jiang H; Kumar M; Yun SP; Kam TI; Mao X; Lee Y; Swing DA; Tessarollo L; Ko HS; Dawson VL; Dawson TM
Brain; 2019 Aug; 142(8):2380-2401. PubMed ID: 31237944
[TBL] [Abstract][Full Text] [Related]
17. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.
Lim KL; Chew KC; Tan JM; Wang C; Chung KK; Zhang Y; Tanaka Y; Smith W; Engelender S; Ross CA; Dawson VL; Dawson TM
J Neurosci; 2005 Feb; 25(8):2002-9. PubMed ID: 15728840
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation].
Hattori N; Machida Y; Noda K
Rinsho Shinkeigaku; 2005 Nov; 45(11):905-7. PubMed ID: 16447759
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein.
Mulherkar SA; Sharma J; Jana NR
J Neurochem; 2009 Sep; 110(6):1955-64. PubMed ID: 19645749
[TBL] [Abstract][Full Text] [Related]
20. Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice.
Fournier M; Roux A; Garrigue J; Muriel MP; Blanche P; Lashuel HA; Anderson JP; Barbour R; Huang J; du Montcel ST; Brice A; Corti O
BMC Neurosci; 2013 Nov; 14():135. PubMed ID: 24192137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
